Drug intelligence / Profile preview

morphine + sevoflurane

Development stage
Unknown
Lead developer
Baxter
Modality
Small Molecules
Administration
Inhalation, Intravenous, Intramuscular, Subcutaneous, Epidural, Intrathecal
01

Overview

Morphine + sevoflurane is a combination of two pharmaceutical agents used in anesthesia and pain management. Morphine is a potent opioid analgesic that acts primarily as an agonist at the mu-opioid receptor, providing significant pain relief and sedation. Sevoflurane is a volatile inhalational anesthetic agent used for induction and maintenance of general anesthesia; it acts by modulating various ligand-gated ion channels in the central nervous system to produce unconsciousness, muscle relaxation, and amnesia. When combined, morphine can reduce the minimum alveolar concentration (MAC) of sevoflurane required to achieve adequate anesthesia in some species, indicating an anesthetic-sparing effect; however, this effect may vary depending on dose and species[1][4]. The combination is typically administered during surgical procedures to optimize both analgesia (from morphine) and hypnosis/anesthesia (from sevoflurane).

02

Targets

HTR3A (5-hydroxytryptamine receptor 3A)CaM (Calmodulin)GRIA1 (AMPA receptor subunit GluA1)GLRA1 (Glycine receptor subunit Alpha-1)MOR (Mu opioid receptor)Nicotinic Acetylcholine ReceptorCaV (Voltage-gated calcium channel protein complex)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)5-HT (Serotonin receptors)

Beyond the preview

Go deeper on morphine + sevoflurane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on morphine + sevoflurane.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call